A new peer-reviewed clinical trial conducted by researchers at Tel Aviv University and Reichman University found that sublingual cannabidiol (CBD) may improve clinical outcomes in patients infected with COVID-19.
Published in The Israel Medical Association Journal, the double-blind, placebo-controlled study included 10 participants who tested positive for SARS-CoV-2. Seven patients received CBD extract administered sublingually, while three received a placebo.
Researchers monitored both clinical responses and inflammatory cytokine levels, which are known to play a significant role in the severity of COVID-19 symptoms.